GALECTIN THERAPEUTICS INC
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | $14.3M-60.9% | $36.6M+13.8% | $32.1M+1.2% | $31.7M+33.2% | $23.8M |
| General and administrative | $5.8M-1.1% | $5.9M-1.3% | $5.9M-10.2% | $6.6M+4.0% | $6.4M |
| Total operating expenses | $20.1M-52.7% | $42.4M+11.5% | $38.1M-0.7% | $38.4M+27.1% | $30.2M |
| Total operating loss | -$20.1M+52.7% | -$42.4M-11.5% | -$38.1M+0.7% | -$38.4M-27.1% | -$30.2M |
| Interest income | $126K-62.7% | $338K+47.0% | $230K+342.3% | $52K+1633.3% | $3K |
| Interest expense | -$7.3M-32.3% | -$5.5M-98.4% | -$2.8M-170.3% | -$1.0M-111.2% | -$489K |
| Change in fair value of derivatives | -$3.5M-703.4% | $588K+236.1% | -$432K-177.6% | $557K+303.6% | $138K |
| Total other expense | -$10.8M-133.0% | -$4.6M-54.1% | -$3.0M-606.1% | -$424K-21.8% | -$348K |
| Net loss | -$30.8M+34.5% | -$47.0M-14.6% | -$41.1M-5.9% | -$38.8M-27.0% | -$30.5M |
| Preferred stock dividends | -$138K+9.8% | -$153K-27.5% | -$120K-23.7% | -$97K+43.3% | -$171K |
| Net loss applicable to common stockholders | -$31.0M+34.4% | -$47.2M-5.3% | -$44.8M-15.3% | -$38.9M-26.6% | -$30.7M |
| Net loss per common share - basic (in Dollars per share) | -$480.00+36.8% | -$760.00-2.7% | -$740.00-13.8% | -$650.00-25.0% | -$520.00 |
| Net loss per common share - diluted (in Dollars per share) | -$480.00+36.8% | -$760.00-2.7% | -$740.00-13.8% | -$650.00-25.0% | -$520.00 |
| Weighted average common and potential common shares outstanding - basic (in Shares) | 63.9M+2.6% | 62.3M+3.6% | 60.2M+1.3% | 59.4M+1.5% | 58.5M |
| Weighted average common and potential common shares outstanding - diluted (in Shares) | 63.9M+2.6% | 62.3M+3.6% | 60.2M+1.3% | 59.4M+1.5% | 58.5M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | 2026-05-28 | Jamil Khurram | Chief Medical Officer | Sale | 568 | $3.10 | $2K | 0 | View | |
| 2026-01-06 | 2026-01-06 | Jamil Khurram | Chief Medical Officer | Sale | 21.4K | $3.65 | $78K | 0 | View | |
| 2026-01-05 | 2026-01-06 | Jamil Khurram | Chief Medical Officer | Sale | 25.5K | $3.90 | $99K | 21.4K | View | |
| 2026-01-02 | 2026-01-06 | Jamil Khurram | Chief Medical Officer | Sale | 13.1K | $4.20 | $55K | 46.9K | View | |
| 2025-12-31 | 2026-01-05 | Jamil Khurram | Chief Medical Officer | Sale | 8,125 | $4.07 | $33K | 0 | View |
Informational purposes only, not investment advice.